Robert Goeltz II - Jan 23, 2023 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Financial Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Jan 23, 2023
Transactions value $
$0
Form type
4
Date filed
1/25/2023, 04:53 PM
Previous filing
Dec 16, 2022
Next filing
Jun 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +34K +115.49% $0.00 63.4K Jan 23, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +138K $0.00 138K Jan 23, 2023 Common Stock 138K $22.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company.
F2 The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company.